亚宝药业终止SY-009的临床研究开发工作，将计提5579.33万元资产减值准备

Core Viewpoint - The company has decided to terminate the clinical research and development of the SY-009 project due to the assessment of its progress, investment risks, and future market value, aiming to allocate resources more effectively to its advantageous projects [1][2] Group 1: Project Termination - The company announced the termination of the SY-009 clinical research project after careful evaluation of its progress and associated risks [1] - The Phase II clinical study results indicated a relationship between dose and effect, but the primary efficacy endpoint was not met, leading to uncertainty in further development [1] - The decision was made following recommendations from the scientific committee and approval from the company's president and chairman [1] Group 2: Financial Implications - The company has fully recognized an asset impairment provision of 55.7933 million yuan for the SY-009 project due to the termination of its clinical research and the lack of potential buyers for related proprietary technology [2]